SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?


To: Colby who wrote (9170)6/4/1998 6:56:00 PM
From: Zebra 365  Read Replies (1) | Respond to of 23519
 
Many of you new to VVUS may not know that anti-hostile takeover provisions are in effect. If a hostile takeover was attempted, your shareholdings would double for a nominal fee. Check the 1997 10-k for the details.

Remember, the stock doesn't know you own it and this crash does not affect the company in any substantial way, except I'm sure they would have been happier to do the repurchase of shares at 6 rather than at 15.

I bought more today, and I'm sorry if I was taking advantage of anyones margin call.

Bidness is bidness, as we say in Texas.

Zebra



To: Colby who wrote (9170)6/4/1998 7:23:00 PM
From: VLAD  Respond to of 23519
 
Colby,

When you call Vivus request to speak to Nina or else they will simply transfer you to her voice mail. Her direct line is 1-650-934-5271.
There is also a guy named David who works with Nina 934-5264.

FWIW, Nina thinks Vivus will eventually be a $60.oo stock. The question is, HOW LONG WILL IT TAKE?

Your question on production are good. I wanted to ask if Nina knew how many units are being absorbed by Astra.

IMO even with a successful launch in England, a loss is expected because 1)increased expenses on new sales force 2)lower US sales where the margins are much higher (Vivus gets $17.00) 3)lower margins in England (Vivus gets somewhere between $6.00-$7.00 but has no expenses other than production and materials.

What I would like to know is what it costs Vivus to produce one unit of MUSE in the new plant. When I say costs I don't mean to include advertising, research or salaries other than factory related employees.